News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,304 Results
Type
Article (43772)
Company Profile (318)
Press Release (697201)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210976)
Career Advice (2106)
Deals (36758)
Drug Delivery (124)
Drug Development (83412)
Employer Resources (176)
FDA (16816)
Job Trends (15497)
News (357326)
Policy (34125)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2610)
Accelerated approval (31)
Adcomms (26)
Allergies (143)
Alliances (51586)
ALS (172)
Alzheimer's disease (1682)
Antibody-drug conjugate (ADC) (318)
Approvals (17077)
Artificial intelligence (526)
Autoimmune disease (151)
Automation (37)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (193)
Biotechnology (188)
Bladder cancer (157)
Brain cancer (59)
Breast cancer (642)
Cancer (4832)
Cardiovascular disease (410)
Career advice (1785)
Career pathing (36)
CAR-T (281)
CDC (47)
Celiac Disease (2)
Cell therapy (745)
Cervical cancer (36)
Clinical research (71090)
Collaboration (1729)
Company closure (4)
Compensation (1156)
Complete response letters (60)
COVID-19 (2782)
CRISPR (93)
C-suite (843)
Cystic fibrosis (148)
Data (6200)
Decentralized trials (2)
Denatured (36)
Depression (133)
Diabetes (503)
Diagnostics (6756)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (250)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (230)
Earnings (91770)
Editorial (58)
Employer branding (21)
Employer resources (154)
Events (120135)
Executive appointments (985)
FDA (19936)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1464)
Gene editing (199)
Generative AI (44)
Gene therapy (607)
GLP-1 (1010)
Government (4796)
Grass and pollen (7)
Guidances (384)
Healthcare (19053)
HIV (55)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (256)
Immuno-oncology (55)
Indications (105)
Infectious disease (3043)
Inflammatory bowel disease (193)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (247)
Interviews (326)
IPO (16917)
IRA (56)
Job creations (4068)
Job search strategy (1497)
JPM (64)
Kidney cancer (15)
Labor market (83)
Layoffs (575)
Leadership (32)
Legal (8422)
Liver cancer (92)
Longevity (15)
Lung cancer (650)
Lymphoma (375)
Machine learning (43)
Management (60)
Manufacturing (806)
MASH (166)
Medical device (13842)
Medtech (13894)
Mergers & acquisitions (20902)
Metabolic disorders (1290)
Multiple sclerosis (160)
NASH (17)
Neurodegenerative disease (318)
Neuropsychiatric disorders (89)
Neuroscience (2925)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4557)
Now hiring (65)
Obesity (610)
Opinion (285)
Ovarian cancer (165)
Pain (215)
Pancreatic cancer (224)
Parkinson's disease (281)
Partnered (34)
Patents (496)
Patient recruitment (479)
Peanut (58)
People (60846)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22068)
Phase 2 (31259)
Phase 3 (23426)
Pipeline (5162)
Policy (294)
Postmarket research (2655)
Preclinical (9378)
Press Release (68)
Prostate cancer (236)
Psychedelics (49)
Radiopharmaceuticals (283)
Rare diseases (857)
Real estate (6305)
Recruiting (71)
Regulatory (25333)
Reports (51)
Research institute (2434)
Resumes & cover letters (360)
Rett syndrome (27)
RNA editing (17)
RSV (76)
Schizophrenia (154)
Series A (243)
Series B (188)
Service/supplier (11)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3763)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (78)
Vaccines (1016)
Venture capital (88)
Weight loss (401)
Women's health (87)
Worklife (18)
Date
Today (79)
Last 7 days (581)
Last 30 days (2070)
Last 365 days (30311)
2026 (2953)
2025 (30682)
2024 (35769)
2023 (40633)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35771)
2017 (33141)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (83)
Alaska (7)
Arizona (312)
Arkansas (14)
Asia (42130)
Australia (6743)
California (11233)
Canada (3279)
China (1129)
Colorado (475)
Connecticut (472)
Delaware (336)
Europe (90265)
Florida (1669)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (870)
India (65)
Indiana (525)
Iowa (22)
Japan (432)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8099)
Michigan (322)
Minnesota (626)
Mississippi (5)
Missouri (127)
Montana (31)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2989)
New Mexico (29)
New York (2966)
North Carolina (1460)
North Dakota (8)
Northern California (5464)
Ohio (332)
Oklahoma (22)
Oregon (46)
Pennsylvania (2276)
Puerto Rico (22)
Rhode Island (47)
South America (1174)
South Carolina (66)
South Dakota (1)
Southern California (4374)
Tennessee (172)
Texas (1739)
United States (39954)
Utah (336)
Vermont (1)
Virginia (272)
Washington D.C. (81)
Washington State (923)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
741,304 Results for "ionis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing
Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.
November 10, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease
By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William Blair.
September 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Approvals
Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease
The drug, for hereditary angioedema, is Ionis’ second wholly owned asset.
August 22, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
Aside from lowering triglyceride levels, Ionis’ olezarsen reduced acute pancreatitis events, an outcome that BMO Capital Markets said could help the asset deliver a “significant first-in-class commercial launch.”
September 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
December 2, 2025
·
4 min read
Press Releases
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
January 12, 2026
·
8 min read
Press Releases
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
November 11, 2025
·
5 min read
Press Releases
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
November 13, 2025
·
8 min read
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
January 7, 2026
·
2 min read
·
Tristan Manalac
1 of 74,131
Next
